In vitro interaction profiles of new anti-TB drugs Bedaquiline, Delamanid with Moxifloxacin against clinical isolates of Mycobacterium tuberculosis
ConclusionSynergistic and additive effects between these two drugs combinations offers an attractive chemotherapeutic regimens against all drug resistant clinical isolates.
Source: Journal of Global Antimicrobial Resistance - Category: Infectious Diseases Source Type: research
More News: Antimicrobial Resistance | Avelox | Bedaquiline | Infectious Diseases | Moxifloxacin | Tuberculosis